Pepkon advances to Semi-finals of EIT Health Catapult 2024-2025
PepKon is honored to be selected as a semi-finalist in the EIT Health Catapult 2024-25, standing alongside Europe’s promising life sciences and healthtech innovators. This achievement highlights our innovative peptides and our mission to advance breakthrough in peptide therapy for leukemia and other diseases.
As part of this elite group, PepKon will gain unmatched industry exposure, mentorship, and access to leading investors, accelerating our path toward clinical development. The competition will finish in April 2025, where the top finalists will compete for funding and strategic support to bring transformative healthcare solutions to patients worldwide.
This milestone reinforces our commitment to pioneering peptide therapeutics and forging impactful partnerships in the biotech ecosystem.
Follow our journey as we shape the future of medicine with our innovative PEPTIDES
